In a new article for the CTC Sentinel, NTI | bio Vice President Jaime Yassif explains how advances in bioscience and biotechnology are accompanied by emerging biological risks and cites the need for action to safeguard the life sciences to prevent biotechnology catastrophe.
Following the recent detection of monkeypox cases across multiple countries, NTI’s report on the exercise has appeared in a number social media outlets, noting that the associated fictional scenario featured a monkeypox outbreak with a start date that roughly coincides with the current, ongoing outbreak.
NTI | bio and the World Economic Forum (WEF) convened the third annual meeting of the Technical Consortium on DNA Synthesis Screening on May 12-13, 2022.
NTI is pleased to announce the appointment of Patricia Jaworek, Mary Fulham, and Emma Stevens.
The Nuclear Threat Initiative celebrated its 20th anniversary at its annual Board of Directors dinner on April 12, 2022 with toasts and a future-focused panel discussion on the importance of innovation in building a safer world.
NTI joined governments and organizations from around the world for the 2nd Global COVID-19 Summit on May 12, 2022 and committed to provide $35,000 to the pandemic preparedness and global health security financial intermediary fund.
NTI Vice President for Nuclear Materials Security Scott Roecker and Program Officer Jessica Bufford presented at the first International Conference on Nuclear Law hosted by the International Atomic Energy Agency (IAEA) in Vienna from March 25-29, 2022.
New approaches to strengthen international safeguards. The papers are the result of a 2021 project aimed at bridging a growing gap between Russian and U.S.-Western views on the effectiveness and sustainability of IAEA safeguards.
More than 40 experts from nuclear operators across 15 countries and several international organizations worked to develop practical steps to strengthen cybersecurity at nuclear facilities during the fifth meeting of NTI’s Cyber-Nuclear Forum earlier this month.
A global leader in science policy with a background in biosecurity, McMurry-Heath is a medical doctor and immunologist whose career spans government, the pharmaceutical industry, and biotechnology.
